MET and triple-negative breast carcinoma: In a previous clinical study, foretinib was shown to have anti-cancer activity in triple-negative breast cancer with the low amplification of Met; foretinib has exerts anti-cancer effects through the inhibition of several pathways, in addition to the HGF/Met pathway.